The Board Members in meeting held today has decided to defer the declaration of an Interim Dividend. While the Company continues to maintain health financial position and robust liquidity, ....
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong FY26 consolidated results with total income of Rs 7,806 million (up 16.5% YoY) and net profit of Rs 1,736 million (up 29.6% YoY). The Board recommended a final dividend of Rs 1.35 per share (67.5% on face value Rs 2) for FY25-26, subject to shareholder approval at the AGM. However, the Board decided to defer the declaration of an interim dividend, citing the need to preserve capital for evaluating potential strategic avenues and corporate actions that could maximize long-term shareholder value. The company maintained healthy financials and robust liquidity. Additionally, 49,350 equity shares were allotted under the ESOP 2022 scheme, and new appointments/reappointments of directors and auditors were approved.
The deferral of interim dividend is a near-term neutral to slightly negative signal for income-focused investors, but the company hints at potential strategic actions (possibly M&A or expansion) that could benefit long-term shareholders. The strong financial performance and proposed final dividend provide some cushion.